Evidence map›Paper›PMID 31851783›Full record

ArticleCancer medicine2020

Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages.

Guanzhang Li, You Zhai, Zheng Wang, Zhiliang Wang, Ruoyu Huang, Haoyu Jiang, Renpeng Li, Yuemei Feng, Yuanhao Chang, Tao Jiang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Optimal managements of elderly patients with glioblastoma.Japanese journal of clinical oncology · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Guanzhang LiDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
You ZhaiDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Zheng WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zhiliang WangDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Ruoyu HuangDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Haoyu JiangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Renpeng LiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuemei FengDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Yuanhao ChangDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Tao JiangDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.ORCID 0000-0002-7008-6351
Wei ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0001-7800-3189
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma is the most malignant tumor of the central nervous system. Several prediction models have been produced to aid in prognosis assessment. Age, a primary decision factor for prognosis, is associated with increased genomic alterations, however the exact link between increased age and poor prognosis is unknown.

objectiveIn this study, we aimed to reveal the underlying cause of poor prognosis in elderly patients.

methodsThis study included data on 616 primary GBM tumor samples from the CGGA and TCGA databases and 41 nontumor brain tissue samples obtained from GSE53890. Hallmarks and clinicopathological characteristics were evaluated in both tumor and nontumor brain tissues. The association between choice of treatment regimen and age was measured using ANOVA and Student's t test.

resultsAge was a robust predictor of poor prognosis in glioma. No age-related hallmarks of cancer were detected, including pathological characteristics or mutations. However, treatment choice was strongly significantly different between old and young patients. Combined chemo-radiation therapy could benefit old and young GBM patients, however, old patients are currently less likely to choose it.

conclusionThe vast divergence in prognosis between young and old GBM patients is largely caused by choice of treatment rather than age-related tumor genomic characteristics. Postoperative standard radio- and chemotherapy provide strong benefits to primary glioblastoma patients of all ages.

Indexed as

Neurosurgical ProceduresPractice Guidelines as TopicAgedAge FactorsBiomarkers, TumorBrainBrain NeoplasmsChemoradiotherapy, AdjuvantClinical Decision-MakingFemaleGlioblastomaHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisBiomarkers, Tumoradjuvant therapyagegenomic alterationglioblastomaprognosis

Identifiers

PMID31851783
PMCPMC7064041
OpenAlexW2995781187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.